ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2812

Healthcare Resource Utilization and Costs in Patients with Systemic Lupus Erythematosus before and after Initiating Treatment with Intravenous Belimumab: A US Claims Database Analysis

Christopher F Bell1, Julie Priest2,3, Marni Stott-Miller4, Hong Kan5, Justyna Amelio6, Xue Song7, Brendan Limone7, Virginia Noxon7 and Karen H. Costenbader8, 1GSK US Value, Evidence and Outcomes, Research Triangle Park, NC, 2GSK US Value, Evidence and Outcomes (at the time of Study)*, Research Triangle Park, NC, 3US Health Outcomes Durham, *ViiV Healthcare (Present), Durham, NC, 4GSK Real World Evidence & Epidemiology, Uxbridge, United Kingdom, 5Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 6GSK Real World Evidence & Epidemiology, Stevenage, United Kingdom, 7Truven Health Analytics, an IBM company, Ann Arbor, MI, 8Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: administrative databases, belimumab, Health care cost, systemic lupus erythematosus (SLE) and treatment

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 7, 2017

Session Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Neuropsychiatric Disease and Health Economics

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. There is limited information on all-cause healthcare resource utilization (HCRU) and costs before/after initiation of belimumab treatment. Data from privately-insured US administrative claims databases can provide valuable descriptive information on HCRU and costs under routine care settings.

Methods: A retrospective analysis (study 206345) was conducted using the Truven Health MarketScan® Commercial Claims and Encounters database (Sept 01, 2010 to Dec 31, 2015). Patients were 18–64 years of age with a SLE diagnosis (ICD-9: 710.0 or ICD-10: M32) and ≥1 belimumab infusion. The index date was the date of the first belimumab infusion. Continuous enrollment was required 6 months pre‑index and ≥3 post‑index date. Here, we present data from patients with 6 months of post‑index follow-up.

Results: This analysis comprised 1879 patients with 6 months of post-index follow-up. The proportion of patients utilizing healthcare services was significantly lower after belimumab initiation versus the pre-index period for inpatient admissions, and for some outpatient services such as emergency room visits, hospital-based outpatient visits and laboratory services (all p<0.001; Table). The number of healthcare services utilized was also significantly lower after initiation versus the pre-index period for inpatient admissions and several outpatient services, including emergency room visits, physician office visits, hospital-based outpatient visits, laboratory services and outpatient pharmacy prescriptions (all p<0.001). Total all-cause healthcare costs were significantly higher following belimumab initiation, compared with the pre-index period (p<0.001). Outpatient service costs, including hospital-based outpatient visits and other outpatient costs, were significantly higher following initiation (all p<0.001). However, inpatient admissions, physician office visits and laboratory costs were significantly lower after initiation (all p<0.001).

Conclusion: This study provides valuable real-world information about HCRU and costs before and after initiation of intravenous belimumab in a large sample of US patients with SLE. While total costs increased in the 6-month follow-up period, in part due to the cost of belimumab, significant reductions in inpatient admissions, emergency room visits and physician office visits, as well as the costs associated with these services were observed. The effect of belimumab treatment on HCRU and costs, particularly beyond the first 6 months, requires further exploration.

Study funded/conducted by GSK. Editorial assistance provided by Jennie McLean, PhD, of Fishawack Indicia Ltd, UK, funded by GSK


Disclosure: C. F. Bell, GSK, 1,GSK, 3; J. Priest, GSK, 1,GSK, 3; M. Stott-Miller, GSK, 1,GSK, 3; H. Kan, GSK, 1; J. Amelio, GSK, 1,GSK, 3; X. Song, Truven Health Analytics, 3; B. Limone, None; V. Noxon, Truven Health Analytics, 3; K. H. Costenbader, Glaxo Smith Kline, 5,Merck Pharmaceuticals, 2,Biogen Idec, 5,AstraZeneca, 5.

To cite this abstract in AMA style:

Bell CF, Priest J, Stott-Miller M, Kan H, Amelio J, Song X, Limone B, Noxon V, Costenbader KH. Healthcare Resource Utilization and Costs in Patients with Systemic Lupus Erythematosus before and after Initiating Treatment with Intravenous Belimumab: A US Claims Database Analysis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/healthcare-resource-utilization-and-costs-in-patients-with-systemic-lupus-erythematosus-before-and-after-initiating-treatment-with-intravenous-belimumab-a-us-claims-database-analysis/. Accessed January 19, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/healthcare-resource-utilization-and-costs-in-patients-with-systemic-lupus-erythematosus-before-and-after-initiating-treatment-with-intravenous-belimumab-a-us-claims-database-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.